Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High – What’s Next?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during trading on Monday . The company traded as high as $38.13 and last traded at $37.80, with a volume of 36516 shares traded. The stock had previously closed at $36.49.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on KNSA shares. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. TD Cowen assumed coverage on shares of Kiniksa Pharmaceuticals International in a report on Monday. They issued a “buy” rating and a $60.00 price target on the stock. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $44.29.

Kiniksa Pharmaceuticals International Price Performance

The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of 946.61 and a beta of 0.20. The stock’s fifty day simple moving average is $33.37 and its two-hundred day simple moving average is $28.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Activity

In related news, insider Ross Moat sold 3,523 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $35.31, for a total value of $124,397.13. Following the sale, the insider owned 9,415 shares of the company’s stock, valued at $332,443.65. This trade represents a 27.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thomas Malley sold 78,233 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the completion of the transaction, the director owned 12,546 shares of the company’s stock, valued at $415,147.14. This represents a 86.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold 561,371 shares of company stock worth $18,825,009 in the last 90 days. 53.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently made changes to their positions in KNSA. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth about $301,000. GAMMA Investing LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 568 shares during the period. Deutsche Bank AG boosted its holdings in shares of Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock worth $8,762,000 after buying an additional 252,125 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth about $1,184,000. Finally, Invesco Ltd. boosted its holdings in shares of Kiniksa Pharmaceuticals International by 137.4% in the first quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock worth $744,000 after buying an additional 19,384 shares during the period. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.